From MDD to MDR: A Strategic Guide for Medical Device Manufacturers
Authors: Hélène Maurer and Zein Nihad
The shift from the Medical Device Directive (MDD) to the Medical Device Regulation (MDR) is more than a regulatory upgrade, it marks a significant transformation in how medical devices are developed, certified, and monitored across the European Union. Officially applicable since May 2021, MDR (EU 2017/745) replaces the more fragmented and less rigorous MDD framework with a harmonized, risk-based system designed to improve safety, traceability, and public confidence.
Unlike the MDD, which permitted variation in interpretation among EU member states, MDR is a directly binding regulation. It enforces stricter and more uniform standards for clinical evaluation, risk classification, post-market surveillance (PMS), and technical documentation.
Why the change? Scandals like the PIP breast implant case exposed major weaknesses in the old system. The MDR was introduced to close these gaps and strengthen oversight across all classes of medical devices.
Explore our Regulatory Affairs support to learn how VGS helps life sciences companies meet evolving EU compliance demands.
Reclassification - Raising the Bar on Risk
How MDR Impacts Device Classification
A major change under MDR is the tightened classification criteria. Devices that were previously classified as low risk under MDD are now often reclassified to higher categories, especially software and reusable surgical instruments.
Examples include:
- Diagnostic software moving from Class I to Class II or higher
- Reusable surgical tools requiring Notified Body involvement even if they remain Class I. These changes lead to longer approval timelines, higher compliance costs, and more rigorous evidence requirements. Expert Advice: Start with a detailed gap assessment. Prioritize high-revenue and high-risk products and align your documentation with the new classification.
Clinical & Technical Documentation - A Lifecycle Approach
MDR demands significantly more robust and continuously updated documentation throughout a product’s lifecycle. Companies must demonstrate that safety and performance are maintained not only at the time of approval but during the entire usage period.
Key Challenges:
- Legacy products lacking historical clinical data
- Underestimating the depth of clinical evaluation now required
- Keeping documentation aligned with real-world data
Best Practices:
- Maintain “living” technical files with regular updates
- Embed MDR compliance into the earliest stages of product development
- Foster collaboration between regulatory, clinical, and R&D teams
Discover how our Clinical Data Management services support continuous evidence generation and audit-ready documentation.
Notified Bodies - Limited Availability, Higher Scrutiny
Notified Bodies (NBs) now play a much more rigorous and centralized role under MDR. They assess technical documentation, clinical evaluations, PMS plans, and labeling. However, the number of accredited MDR NBs is significantly lower than under MDD—leading to backlogs and delays.
Consequences:
- Extended review periods
- Postponed product launches
- Potential loss of market access due to expired MDD certificates
Planning Tip: Engage early with Notified Bodies, align your documentation format with their expectations, and build buffer time into your compliance roadmap.
Strategic Decision-Making - Transition, Redesign, or Retire
Not every product will justify the cost of MDR compliance. Manufacturers are carefully reviewing their portfolios to decide whether to:
- Transition products that are strategic or revenue-generating
- Redesign to meet new criteria or reduce classification risk
- Retire products that are low-margin or outdated
Specialist Insight: Focus on devices with high strategic value. Consider redesign options and evaluate global markets where regulatory burdens may differ.
Communication & Market Access - Staying Aligned and Transparent
Transparency is no longer optional. MDR requires that all marketing claims, labeling, and Instructions for Use (IFUs) be backed by verifiable clinical evidence. Clear communication, both internally and externally, is essential.
Who Needs to Be Informed:
- Regulatory authorities
- Distribution and supply chain partners
- Healthcare professionals and end users
Pro Tip: Ensure that all stakeholders are aligned on timelines and compliance messaging. Transparency reinforces your brand's commitment to safety and quality.
Lessons from the Field - How Consulting Expertise Accelerates MDR Readiness
In large-scale MDR transitions, specialized consultants play a vital role across planning, implementation, and post-market support.
In a major EU-based MDR project, VGS consultants:
- Updated 300,000+ product labels
- Developed MDR-compliant UDI and documentation templates
- Segregated MDD vs MDR inventory at primary distribution centers
- Conducted verification audits across European logistics hubs
- Acted as Single Points of Contact for regulatory teams
By embedding regulatory consultants into operational teams, VGS enabled faster decision-making, better alignment, and smoother communication between global business units.
Learn more about our Functional Service Provider (FSP) model, and how it offers embedded, scalable regulatory expertise.
Final Advice - Treat MDR as a Business Transformation
This transition isn’t just a regulatory milestone, it’s an enterprise-wide transformation. Successful MDR projects require:
- Executive sponsorship
- Cross-functional alignment
- Advanced planning and program leadership
Final Thought from the Experts:
“Approach MDR as a strategic transformation, not just a compliance checkbox. Start early, stay proactive, and build the right team to lead the change.”
Ready to simplify your MDR transition? Let VGS help. From documentation and classification to audit support and program leadership, we partner with companies across the globe to accelerate compliance and ensure business continuity.
